Genetic Testing Revolution: Targeted Sequencing for Faster, More Accurate Results
"Discover how targeted sequencing is streamlining genetic diagnostics, offering a cost-effective and efficient way to detect chromosome imbalances and single nucleotide variants."
Genetic variations are a key factor in human diversity and disease, making accurate detection crucial. Traditionally, methods like chromosomal microarray testing (CMA) have been used to identify copy number variations (CNVs) across the genome. While CMA has improved diagnostics, it only detects a fraction of genetic disorders, often leading to further, more complex testing.
The need for multiple tests adds time and cost, highlighting the demand for a more streamlined approach. High-throughput sequencing is emerging as a powerful solution, capable of detecting both CNVs and single nucleotide variants (SNVs) in a single test. This advancement marks a significant step towards comprehensive genetic diagnostics.
Targeted sequencing, a method that enriches specific genomic regions from a DNA sample, is rapidly gaining popularity. By focusing on areas of interest, this technique reduces sequencing costs and analysis time. Clinically focused exome sequencing, targeting the coding regions of the human genome, offers a particularly cost-effective approach to sequence investigation.
Growing Adoption of Genetic Testing
Next-generation sequencing (NGS) has transformed genomics by enabling rapid, high-throughput analysis of DNA and RNA, driving significant progress across cancer research, rare disease diagnosis, and personalized medicine. The technology allows researchers to identify genetic variants that guide targeted therapeutic development. However, assessing the full impact of genetic testing on clinical practice remains challenging due to a lack of structural data in electronic health records (EHRs). Modern sequencing and computational technology now enable researchers to study genetic information faster and more accurately than ever before.
Evolution of Sequencing Approaches
Hereditary cancer testing has progressed from single-gene assays to multigene panel testing, and now toward broader exome, genome, and long-read sequencing approaches. RNA testing was traditionally performed with RT-PCR using primers overlapping exons followed by Sanger sequencing, but the emergence of targeted RNA sequencing (RNA-seq) offers a more scalable approach. A blinded, prospective study systematically compared singleton genome sequencing, trio genome sequencing, and exome sequencing-based standard-of-care genetic testing in 416 patients with rare diseases. Despite technical advantages, the full clinical utility of genome sequencing in real-world diagnostic settings remains to be fully established.
Foundations of Genetic Testing
Genetic testing has evolved significantly since the development of DNA sequencing methods in the 1970s and 1980s. The completion of the Human Genome Project in 2003 marked a pivotal milestone, providing the first comprehensive map of human genetic information. These foundational discoveries laid the groundwork for the development of targeted sequencing technologies and personalized medicine approaches used today.
How Targeted Sequencing Improves Genetic Detection
Researchers have evaluated a targeted sequencing approach that combines a clinically focused exome panel with a backbone and SNP probes. This allows for the detection of genome-wide copy number changes and copy-neutral absence of heterozygosity (AOH), potentially replacing traditional chromosomal microarray testing and sequencing with a single, more efficient test.
- The DNA panel included CNVs of varying sizes (23 Kb to 27 Mb).
- Uniparental disomy (UPD).
- Single point mutations.
Advances in Targeted Sequencing
Next-generation sequencing platforms have enabled whole-genome sequencing, transcriptome analysis, and targeted sequencing, leading to breakthroughs in understanding genetic variation and disease. Recent reviews discuss experimental and computational advances in single-cell DNA sequencing, providing insights into somatic genetic variation during normal development and in disease states. Targeted next-generation sequencing (tNGS) has emerged as an upcoming clinical tool, with the advantages of high sensitivity, high efficiency, and relatively low cost compared to broader sequencing approaches.
Challenges in Genetic Testing Implementation
While next-generation sequencing technologies have been instrumental in cancer genomics and precision oncology, they come with significant limitations that must be acknowledged. An observational study illustrates examples of pitfalls and challenges in interpretation of genetic testing results as reported by genetics professionals, highlighting the complexity of variant interpretation. There is an important qualitative difference between patients' experiences when confronted with traditional diagnostic testing results versus whole-exome sequencing and direct-to-consumer genetic testing. Although the sensitivity of assays to detect typical disease-related variants is very high, failure to detect certain types of genetic alterations may result from technical limitations in DNA sequencing and computer-assisted analysis.
Evaluating Sequencing Strategies
Different sequencing strategies offer varying levels of comprehensiveness and clinical utility depending on the specific application. Targeted sequencing approaches focus on specific genes or regions of interest, while whole-genome and whole-exome sequencing provide broader coverage of genetic information. The choice of sequencing strategy involves trade-offs between cost, turnaround time, data complexity, and clinical utility. Healthcare providers must consider these factors when selecting the most appropriate testing approach for individual patients and clinical scenarios.
The Future of Genetic Testing with Targeted Sequencing
The study highlights the promising potential of targeted sequencing for CNV detection, achieving resolution and sensitivity similar to or even greater than microarrays. This advancement streamlines the study of chromosome abnormalities directly from DNA sequence data, reducing time and costs. It means that a single platform can be used to test a large amount of diseases.
Universal vs Guided Testing Approaches
A cohort study examined the prevalence of pathogenic germline variants in patients with cancer using a universal testing approach compared with targeted testing based on clinical guidelines. The study also assessed subsequent uptake of cascade family variant testing following each approach. An ASCO provisional clinical opinion offers timely clinical direction regarding the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors, reflecting evolving standards in the field.
Emerging Trends in Genetic Testing
The Genetics Outlook Report 2025 explores how trends like next-generation sequencing and synthetic biology will contribute to the future of medicine, treatments, and drug developments. Genetic testing is transforming healthcare from a reactive model to a proactive, predictive system, with advances in sequencing, AI, and digital health making genomic insights more precise and widely accessible. A report by the FDA highlights that approximately 70% of new drug applications include genetic biomarkers, indicating the integral role of targeted sequencing in drug development and personalized medicine. Growing insurer support and consumer trust are driving mainstream adoption of genetic testing technologies.
Healthcare System Integration
Integrating genetic testing into routine clinical practice requires addressing systemic challenges related to infrastructure, education, and equitable access. Healthcare systems must develop frameworks for storing, sharing, and interpreting genomic data while maintaining patient privacy and security. Training healthcare professionals in genomic medicine and ensuring adequate genetic counseling resources remain ongoing challenges. These systemic considerations are essential for realizing the full potential of genetic testing across diverse patient populations.
Clinical Utility in Practice
Real-world case studies demonstrate the clinical utility of next-generation sequencing in actual patient care settings. In one example, rapid whole genome sequencing helped diagnose a newborn with Severe Combined Immunodeficiency (SCID), commonly known as 'bubble boy disease,' pinpointing the exact type and guiding life-saving treatment decisions. Targeted NGS has played a pivotal role in the diagnosis and treatment of cancer patients, as illustrated by representative cases where genomic testing directly influenced clinical management. These cases highlight how genetic testing translates from laboratory technology to meaningful patient outcomes.
As next-generation sequencing technologies continue to advance, sequencing data is poised to replace the combined use of traditional diagnostic methods like CMA and sequencing in clinical and research settings. This transition will bridge the resolution gap between CNVs detected by microarrays and indels identified by sequencing, enhancing our understanding of normal and pathogenic DNA copy number variations.
Targeted sequencing offers a practical and efficient approach, streamlining processes and enhancing the precision of genetic diagnoses. This will lead to easier implementation within clinical labs.